United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - everolimus - dispersible tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - everolimus - dispersible tablet - 3mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - everolimus - dispersible tablet - 5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - everolimus - tablet - 2.5 milligram(s) - protein kinase inhibitors; everolimus

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - everolimus +0.2% bht - tablet - 2.50 mg - everolimus +0.2% bht 2.50 mg

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - everolimus - carcinoma, renal cell; breast neoplasms; pancreatic neoplasms - antineoplastic agents - hormone-receptor-positive advanced breast cancerafinitor is indicated for the treatment of hormone-receptor-positive, her2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.neuroendocrine tumours of pancreatic originafinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.neuroendocrine tumours of gastrointestinal or lung originafinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (grade 1 or grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.renal-cell carcinomaafinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with vegf-targeted therapy.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - everolimus - tuberous sclerosis - antineoplastic agents - renal angiomyolipoma associated with tuberous sclerosis complex (tsc)votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (tsc) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.the evidence is based on analysis of change in sum of angiomyolipoma volume.subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc)votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not amenable to surgery.the evidence is based on analysis of change in sega volume. further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novartis pharma stein ag - everolimus - tablets - 5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

novartis pharma stein ag - everolimus - tablets - 10mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus